VEA
ABCL icon

Virtus ETF Advisers’s AbCellera Biologics ABCL Stock Holding History

Virtus ETF Advisers’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-24,099
Closed -$70.6K – 420
2024
Q4 		$70.6K Sell
24,099
-3,579
-13% -$9.97K 0.03% 373
2024
Q3 		$72K Buy
27,678
+493
+2% +$1.37K 0.03% 425
2024
Q2 		$80.5K Buy
27,185
+11,373
+72% +$43K 0.04% 404
2024
Q1 		$71.6K Sell
15,812
-1,082
-6% -$5.52K 0.04% 409
2023
Q4 		$96.5K Buy
16,894
+3,509
+26% +$16.3K 0.06% 374
2023
Q3 		$61.6K Sell
13,385
-1,329
-9% -$8.09K 0.04% 402
2023
Q2 		$95.1K Buy
14,714
+4,731
+47% +$32.3K 0.06% 409
2023
Q1 		$75.3K Sell
9,983
-3,844
-28% -$34.9K 0.04% 394
2022
Q4 		$140K Buy
13,827
+1,951
+16% +$22.5K 0.07% 366
2022
Q3 		$117K Buy
11,876
+92
+0.8% +$1.01K 0.05% 401
2022
Q2 		$125K Hold
11,784
– – 0.05% 369
2022
Q1 		$115K Sell
11,784
-698
-6% -$6.61K 0.05% 278
2021
Q4 		$178K Buy
12,482
+3,818
+44% +$57.9K 0.07% 252
2021
Q3 		$174K Sell
8,664
-447
-5% -$7.9K 0.08% 301
2021
Q2 		$200K Buy
+9,111
New +$251K 0.08% 346

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Virtus ETF Advisers's ABCL Position: Q1 2025 in Review

Virtus ETF Advisers sold out of AbCellera Biologics (ABCL) in Q1 2025, closing a stake of 24,099 shares — an estimated $70.6K sold.

Virtus ETF Advisers first reported a position in ABCL in Q2 2021 and held it in 15 quarters. The position peaked at $200K in Q2 2021. 129 funds tracked by Wall St. Rank hold ABCL as of Q1 2025.

  • Virtus ETF Advisers reported no remaining AbCellera Biologics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 24,099 AbCellera Biologics shares in Q1 2025, an estimated $70.6K.
  • Virtus ETF Advisers first reported a position in AbCellera Biologics in Q2 2021 and held it in 15 quarters.
  • Virtus ETF Advisers's AbCellera Biologics position peaked at $200K in Q2 2021.
  • 129 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.